Literature DB >> 22300094

Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction.

Diwahar Narasimhan1, James H Woods, Roger K Sunahara.   

Abstract

Cocaine is highly addictive and there are no pharmacotherapeutic drugs available to treat acute cocaine toxicity or chronic abuse. Antagonizing an inhibitor such as cocaine using a small molecule has proven difficult. The alternative approach is to modify cocaine's pharmacokinetic properties by sequestering or hydrolyzing it in serum and limiting access to its sites of action. We took advantage of a bacterial esterase (CocE) that has evolved to hydrolyze cocaine and have developed it as a therapeutic that rapidly and specifically clears cocaine from the subject. Native enzyme was unstable at 37°C, thus limiting CocE's potential. Innovative computational methods based on the protein's structure helped elucidate its mechanism of destabilization. Novel protein engineering methodologies were applied to substantially improve its stability in vitro and in vivo. These improvements rendered CocE as a powerful and efficacious therapeutic to treat cocaine intoxication and lead the way towards developing a therapy for addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22300094      PMCID: PMC3290992          DOI: 10.4155/fmc.11.194

Source DB:  PubMed          Journal:  Future Med Chem        ISSN: 1756-8919            Impact factor:   3.808


  77 in total

Review 1.  Strategies to extend plasma half-lives of recombinant antibodies.

Authors:  Roland E Kontermann
Journal:  BioDrugs       Date:  2009       Impact factor: 5.807

2.  Effects of cocaine esterase following its repeated administration with cocaine in mice.

Authors:  Mei-Chuan Ko; Diwahar Narasimhan; Aaron A Berlin; Nicholas W Lukacs; Roger K Sunahara; James H Woods
Journal:  Drug Alcohol Depend       Date:  2009-02-13       Impact factor: 4.492

3.  Finding better protein engineering strategies.

Authors:  Romas J Kazlauskas; Uwe T Bornscheuer
Journal:  Nat Chem Biol       Date:  2009-08       Impact factor: 15.040

Review 4.  Substance abuse vaccines.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 5.  Amyloid-cholinesterase interactions. Implications for Alzheimer's disease.

Authors:  Nibaldo C Inestrosa; Margarita C Dinamarca; Alejandra Alvarez
Journal:  FEBS J       Date:  2008-01-17       Impact factor: 5.542

6.  Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity.

Authors:  Daquan Gao; Diwahar L Narasimhan; Joanne Macdonald; Remy Brim; Mei-Chuan Ko; Donald W Landry; James H Woods; Roger K Sunahara; Chang-Guo Zhan
Journal:  Mol Pharmacol       Date:  2008-11-05       Impact factor: 4.436

7.  L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL).

Authors:  Young Min Kwon; Hee Sun Chung; Cheol Moon; James Yockman; Yoon Jeong Park; Scott D Gitlin; Allan E David; Victor C Yang
Journal:  J Control Release       Date:  2009-07-03       Impact factor: 9.776

8.  Aripiprazole blocks acute self-administration of cocaine and is not self-administered in mice.

Authors:  Gunnar Sørensen; Thomas N Sager; Jørgen H Petersen; Lise T Brennum; Peter Thøgersen; Cecilie Hee Bengtsen; Morgane Thomsen; Gitta Wörtwein; Anders Fink-Jensen; David P D Woldbye
Journal:  Psychopharmacology (Berl)       Date:  2008-05-15       Impact factor: 4.530

9.  Most efficient cocaine hydrolase designed by virtual screening of transition states.

Authors:  Fang Zheng; Wenchao Yang; Mei-Chuan Ko; Junjun Liu; Hoon Cho; Daquan Gao; Min Tong; Hsin-Hsiung Tai; James H Woods; Chang-Guo Zhan
Journal:  J Am Chem Soc       Date:  2008-08-19       Impact factor: 15.419

10.  Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals.

Authors:  Roberta Kahn; Kousick Biswas; Anna-Rose Childress; Steve Shoptaw; Paul J Fudala; Liza Gorgon; Ivan Montoya; Joseph Collins; Frances McSherry; Shou-Hua Li; Nora Chiang; Husam Alathari; Donnie Watson; Joseph Liberto; Thomas Beresford; Christopher Stock; Christopher Wallace; Valerie Gruber; Ahmed Elkashef
Journal:  Drug Alcohol Depend       Date:  2009-05-02       Impact factor: 4.492

View more
  8 in total

Review 1.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

2.  Butyrylcholinesterase levels and subjective effects of smoked cocaine in healthy cocaine users.

Authors:  Paula Askalsky; Raj K Kalapatapu; Richard W Foltin; Sandra D Comer
Journal:  Am J Drug Alcohol Abuse       Date:  2014-10-16       Impact factor: 3.829

Review 3.  Design, challenge, and promise of stimuli-responsive nanoantibiotics.

Authors:  Julius A Edson; Young Jik Kwon
Journal:  Nano Converg       Date:  2016-10-15

4.  Ibrutinib as a potential therapeutic for cocaine use disorder.

Authors:  Spencer B Huggett; Jeffrey S Hatfield; Joshua D Walters; John E McGeary; Justine W Welsh; Trudy F C Mackay; Robert R H Anholt; Rohan H C Palmer
Journal:  Transl Psychiatry       Date:  2021-12-08       Impact factor: 6.222

Review 5.  A Review of Immunotherapeutic Approaches for Substance Use Disorders: Current Status and Future Prospects.

Authors:  Muhammet Celik; Brian Fuehrlein
Journal:  Immunotargets Ther       Date:  2022-09-29

Review 6.  The neurocircuitry of illicit psychostimulant addiction: acute and chronic effects in humans.

Authors:  Sara B Taylor; Candace R Lewis; M Foster Olive
Journal:  Subst Abuse Rehabil       Date:  2013-02-08

Review 7.  New Insights into the Microbiota of Moth Pests.

Authors:  Valeria Mereghetti; Bessem Chouaia; Matteo Montagna
Journal:  Int J Mol Sci       Date:  2017-11-18       Impact factor: 5.923

Review 8.  Detoxifying symbionts in agriculturally important pest insects.

Authors:  Tijs J M van den Bosch; Cornelia U Welte
Journal:  Microb Biotechnol       Date:  2016-12-12       Impact factor: 5.813

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.